Business
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes
This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approved by the
About this update from Icecure Medical Ltd.
[{"type":"text","content":"This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approved by the NMPAProducts to be distributed in China through agreement with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co. Ltd.Ongoing physician awareness and education efforts will potentially accelerate market acceptance for novel technology and deliver better patient outcomes for those suffering from malignant and benign tissue of the breast, lung, bone, liver, and kidneys, as well as palliative interventionsCAESAREA, Israel, March 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System (marketed under the brand name IceSense3 in China), that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the National Medical Products Administration (\"NMPA\") of China approved the Company's IceSense3 disposable cryoprobes for commercial use, to be used in combination with the Company's IceSense3 console, which was previously approved by the NMPA.\n \nWith this latest approval, the Company and its partners in China can address a significant market with its novel and proven technology to treat malignant and benign tissue of the breast, lung, bone, liver, and kidneys, as well as palliative interventions.\n\"With approximately 430,000 new breast cancer cases in 2022 alone, and a healthcare system readily adopting new technologies that produce improved outcomes, we see China as a prime market for our cryoablation system,\" stated Eyal Shamir, IceCure's Chief Executive Officer. \"Having received regulatory approval for commercial sales of both our console and cryoprobes, we expect to effectively monetize our distribution agreement in the Chinese market.\"\nAbout IceCure Medical Ltd.\nIceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that...